Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.1.1.8 (cholinesterase)
 12,691 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

To evaluate abnormal secretion of growth hormone (GH) in cases of liver diseases, the authors performed a loading test of growth hormone-releasing factor (GRF) and approximately one week later, a loading test of thyrotropin-releasing hormone (TRH), and measured serum GH in 15 cases of liver cirrhosis (LC), 5 with chronic active hepatitis (CAH), and 5 controls. In the TRH test, 8 of 15 LC patients showed a peak GH value of 6 ng/ml or more and were classified as the TRH-responder group (LC-R). Seven other LC patients showing a peak GH value of less than 6 ng/ml were classified as the TRH-non-responder group (LC-NR). None of the CAH cases or controls showed a peak GH value of 6 ng/ml or more. In GRF test, the response of GH was poor in all 8 in the LC-R group. The responses in the LC-NR group were significantly greater than those in the LC-R group from 15 to 90 minutes after the GRF loading. In the LC-R group, greater impairment of liver function was indicated by total bilirubin, serum protein and cholinesterase values compared to the LC-NR group. Fischer's ratio was significantly lower in the LC-R group. In cases of liver diseases, Fischer's ratios negatively correlated with the peak GH values in the TRH test (r = -0.679, P less than 0.01). These results suggest that in LC cases showing a paradoxical GH response to TRH, the GH response to GRF which is a GH stimulatory hormone, is decreased.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Abnormal GH secretion in liver cirrhosis: evaluation of using GRF test and TRH test. 162 79

We examined the possibility that abnormalities of growth hormone (GH) release in cirrhotic patients were related to a reduction in the ratio of branched chain amino acids (BCAAs) to aromatic amino acids (AAAs) in plasma. The intravenous infusion of 250 micrograms of thyrotropin-releasing hormone (TRH) caused a significant rise in plasma GH greater than 5 ng/ml and more than twice as much as the basal levels in 7 out of 15 patients (responders) but an insignificant rise in the remaining patients (non-responders). The difference in the basal GH level was not significant. The oral glucose load suppressed plasma GH in all of the normal subjects and 6 of 7 non-responders, while it was elevated in 6 of 7 responders and one of the non-responders. The ratio of BCAAs to AAAs in the plasma of cirrhotic patients was 1.21 +/- 0.38, which was significantly lower than that of normal subjects (3.31 +/- 0.42, p less than 0.01). In addition, there was a significant difference between responders and non-responders in the ratios (0.96 +/- 0.22 vs 1.42 +/- 0.36, p less than 0.05). An inversely significant correlation (p less than 0.05) between the ratios of BCAAs to AAAs in plasma and the peak levels of GH after TRH injection was observed when all subjects were combined, but no correlation was found between the ratios and the peak levels of GH after oral glucose loading. There were also significant correlations (p less than 0.01) between the ratios and various parameters including the serum albumin, cholinesterase and indocyanine green disappearance rate constant (KICG).(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Interrelation between plasma amino acid composition and growth hormone secretion in patients with liver cirrhosis. 644 Jul 84